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Integrated Continuous Biomanufacturing (ICB) provides many important strategic advantages for therapeutic 
protein production through process intensification, simplification and integration. The success of this technology 
will be significantly enhanced by the platform’s ability to push towards high productivity in conjunction with 
minimizing the associated perfusion rate, resulting in dramatic reductions in cost of good manufactured. We 
have previously demonstrated that an in-house chemically defined medium can support cell densities exceeding 
100 million viable cells/mL in 10L perfusion bioreactors with an average productivity of 2 g/L/day. Further 
optimization utilizing high throughput technology specifically tailored to improve cell specific productivity (SPR) 
resulted in an intensified medium that is capable of achieving greater than 2X increase in SPR while maintaining 
low cell specific perfusion rate (CSPR). When combined with process knowledge and efforts to improve shear 
protection in a high oxygen demand environment, we were able to achieve 4 g/L/day volumetric productivity of 
an IgG for over 30 days in a state of control.  In this talk, recent case studies on the application of this intensified 
perfusion platform to cell lines producing different classes of biologics will be described, effects on product 
quality will be illustrated, and engineering and economic considerations for commercial scale will be discussed. 
 
